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Abstract: Approximately one in four pregnancies result in pregnancy loss, and ~50% of these
miscarriages are caused by chromosomal abnormalities. Genetic investigations are recommended
after three consecutive miscarriages on products of conception (POC) tissue. Cell-free DNA (cfDNA)
has been utilised for prenatal screening, but very little work has been carried out in nonviable
pregnancies. We investigated the use of cfDNA from maternal blood to identify chromosomal
abnormalities in miscarriage. One hundred and two blood samples from women experiencing
a first trimester miscarriage were collected and stored. The mean gestational age was 7.1 weeks
(range: 5–11 weeks). In this research, samples without a genetic test result from POC were not analysed.
CfDNA was extracted and analysed using a modified commercial genome-wide non-invasive prenatal
test. No results were provided to the patient. In 57 samples, cytogenetic results from POC analysis were
available. Chromosomal abnormalities were identified in 47% (27/57) of POC analyses, and cfDNA
analysis correctly identified 59% (16/27) of these. In total, 75% (43/57) of results were correctly
identified. The average cfDNA fetal fraction was 6% (2–19%). In conclusion, cfDNA can be used to
detect chromosomal abnormalities in miscarriages where the ‘fetal fraction’ is high enough; however,
more studies are required to identify variables that can affect the overall results.
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1. Introduction
Early pregnancy loss is the most common complication during pregnancy [1], and is defined as
miscarriage. One in five pregnancies ends in spontaneous miscarriage [2], and 50% of these are due to
chromosomal abnormalities [3]. It is important to identify whether a chromosomal abnormality was
the underlying etiology of the pregnancy loss because this may have an indication for the prognosis
of future pregnancies. If a sporadic chromosomal abnormality is the cause of the pregnancy loss,
the prognosis for future pregnancies is better than if the chromosome complement is normal. In which
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case, there may be another non-chromosomal, reason for the miscarriage. If there is an unbalanced
chromosomal rearrangement in the pregnancy loss, it could mean that one of the parents carries a
balanced chromosomal rearrangement. This would mean that future pregnancies would be susceptible
to the same or other unbalanced rearrangement. In these cases, it is important to obtain blood samples
for parental karyotyping for assessment of recurrence risk.
The Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 17 [4]
recommends cytogenetic analysis of pregnancy tissue after the third and subsequent miscarriages,
or karyotyping of parental samples if pregnancy tissue is not available. Traditionally, cell culture and
G banded chromosomal analysis were used to detect abnormalities in pregnancy tissue. However,
there is often a high failure rate, due to the poor quality of tissue received, the difficulty with culturing
cells from such tissues and a limited resolution in detecting micro-deletion and duplication syndromes.
Therefore, molecular-based approaches, such as quantitative fluorescent PCR (QF-PCR) and microarray
have been implemented across laboratories.
Currently, genetic testing for miscarriage is completed on pregnancy tissue, which comprises
of placental and fetal components, referred to as products of conception (POC). This tissue needs
to be fresh, uncontaminated, and unfixed so that the fetal tissues can be identified and have DNA
extraction or cell culture performed. This comes with the risk of potential maternal cell contamination
(MCC) which could lead to misdiagnosis of the sample. The POC samples contain maternal tissues
intertwined with fetal tissues. Maternal cells can be carried over during the selection of fetal tissues
resulting in maternal DNA during DNA extraction or an overgrowth of maternal cells during cell
culture. Moreover, in many cases, POC are unavailable, or unreturned by the patient.
Cell-free DNA (cfDNA) was first identified by Dennis Lo [5] who demonstrated that small
fragments of cfDNA from the plasma of pregnant women represent the entire fetal genome.
Although cfDNA is already utilised for prenatal screening, very little work has been carried out
in nonviable pregnancies to date. Only two studies by Clark-Ganheart el al. and Yaron et al. [6,7] have
evaluated the use of cfDNA in a miscarriage setting.
A prospective cohort study Clark-Ganheart et al. [6] analysed 50 cfDNA samples of non-viable
pregnancies. Gestational age determined by ultrasound scan ranged from 6.1 to 38.4 weeks.
Among these, 38 of the 50 samples had a reportable result, including eight samples which demonstrated
trisomies. The study by Yaron et al. [7] tested cfDNA to analyse pregnancy loss at less than 14 weeks.
In total, 86 pregnancies had cfDNA results with comparable POC (from CVS sampling). The median
fetal fraction was 5%. Out of the 86 samples, 55 (64%) had a chromosomal abnormality and 30 of
those (55%) were detected using standard non-invasive prenatal testing (NIPT) log-likelihood ratio
(LLR) cut-offs. To increase the sensitivity, a pregnancy-loss specific threshold was developed using a
50 sample ‘training set’. This increased the detection rate to 82%.
CfDNA would be extremely useful to ascertain chromosomal causes of miscarriages at the point
of miscarriage diagnosis by a simple blood test. This study investigates how cfDNA can be utilised to
detect chromosomal abnormalities in miscarriage and to compare the results with those of POC testing.
2. Materials and Methods
2.1. Ethical Approval
The study was completed at Tommy’s National Centre for Miscarriage Research, with IRAS
project ID, 215646, that received Research Ethics Approval (REC reference: 16/WM/0423, 23/11/2016,
West Midlands-South Birmingham Research Ethics Committee) and Health Research Authority
(HRA) approval.
2.2. Patient Samples
Informed consent was obtained from patients experiencing early miscarriage and seen at Tommy’s
National Centre for Miscarriage Research hosted by Birmingham Women’s and Children’s Hospital
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NHS Trust and University Hospital Coventry & Warwickshire NHS Trust between February 2017 and
July 2019. The consent explicitly included consent to work with the patient’s POC and genetic material.
Samples were collected as donations to medical research and the tissue(s) were handled in accordance
with the Human Tissue Act (HTA). The donors maintained their ability to withdraw consent for further
use but did not retain any rights to the samples after acquisition.
Eligibility criteria included maternal age over 16 years and a gestational age of <12 weeks
confirmed by ultrasound scan at the time of miscarriage diagnosis with pregnancy tissue remaining
in situ. Samples were included in analysis in cases where there was a cytogenetic result from
corresponding POC analysis, except in the case of seven known triploid cases, which were excluded.
Blood samples were taken for cfDNA analysis and to assess βhCG levels. Up to 10 mL of maternal
blood was collected for cfDNA in cell-free DNA BCT (STRECK) tubes, and crown-rump length (CRL)
measurements were taken by ultrasound where possible to assess the fetal gestation. Chromosomal
abnormalities obtained from POC testing were communicated to the patient via standard patient care.
CfDNA results were not shared with the patient.
2.3. Sample Processing
Plasma was isolated from whole blood using double centrifugation and transferred into a DNA
LoBind tubes (Eppendorf) in 1 mL aliquots. These aliquots were stored at −80 ◦C until use.
2.4. Cytogenetic Analysis
Products of conception (POC) were collected as routine clinical samples and targeted QF-PCR
and chromosomal microarray analysis (CMA) was completed on POC after the third and subsequent
consecutive miscarriages(s) according to the RCOG Green-top Guideline No. 17 [4].
QF-PCR trisomy screen was first performed on DNA from POC to test for trisomies 13, 18 or 21,
triploidy and sex chromosome aneuploidy. If the QF-PCR was abnormal, then it was reported. If it
was normal, then CMA testing was carried out using OGT CytoSure 8 × 60 k Constitutional v3 design;
exon/gene level resolution of ~500 DDD/ClinGen curated developmental genes and syndromic regions;
tiered backbone resolution ~120–500 kb; analysis in build GRCh37 using CytoSure v4.9 and CBS
algorithm. The microarray analysis detected copy number imbalances >1 Mb and in some cases had
higher resolution.
2.5. Cell-free DNA Testing
Plasma (1 mL) from patients who had consented to testing by an external laboratory were
submitted to the Illumina laboratory in Cambridge and processed in a 24-sample batch through a
modified Illumina VeriSeq NIPT solution v2 workflow as previously described [8,9], but using the
latest analysis platform [10] and with a few small modifications.
3. Results
In total, 102 cfDNA samples were collected once a miscarriage had been confirmed. All 102 samples
were analysed by VeriSeq NIPT v2 Solution analysis on a NextSeq500. Eighty-five corresponding
POC samples were received. In total, 64 pregnancies had a corresponding cytogenetic result from
POC analysis, 21 POC samples were not suitable for analysis and 17 cfDNA samples did not receive
corresponding POC samples. The 17 unreceived POC samples and the 21 POC samples not suitable for
analysis were excluded from cfDNA analysis, and known triploid pregnancies were excluded (Figure 1).
Chromosomal abnormalities were identified by POC analysis in 27/57 (47%) cases. Patient baseline
characteristics are summarised in Table 1. From the 57 samples with corresponding cytogenetic
analysis, the average age was 34 years (20–43 years), with a clinical gestation of 7.1 weeks (5–11 weeks)
and a fetal fraction of 6% (2–19%). In total, 70% (40/57) of samples including 16/27 (59%) of genetic
abnormalities and 27/30 (90%) of genetically normal samples were identified correctly using VeriSeq.
J. Clin. Med. 2020, 9, 3428 4 of 11
This corresponds to a sensitivity of 59% (16/27), specificity of 90% (27/30) and accuracy of 75% (43/57),
although the sample cohort was relatively small.
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Table 1. Characteristics of cfDNA samples with corresponding products of conception (POC) results
suitable for analysis (excluding triploid pregnancies).
Total (n = 57) ChromosomallyNormal (n = 30)
Chromosomally
Abnormal (n = 27)
Maternal age (years) (mean and range) 34 (20–43) 31 (20–41) 37 (24–43)
Previous losses (mean and range) 3.8 (0–14) 4.1 (0–14) 3.3 (0–6)
Gestational age (weeks) (mean and range) 7.1 (5–11) 7.4 (5–11) 6.4 (5–9.3)
βhCG (mIU/mL) (mean and range) 38,356 (69–263,766) 50,632 (69–263,766) 21,538 (491–100,638)
Fetal fraction (%) (mean and range) 6 (2–19) 7 (2–19) 5 (3–12)
CfDNA analysis correctly identified 43/57 (75%) of samples including 16 abnormal and 27 normal
samples. Table 2 compares POC results and cfDNA test results of the cases where an abnormal
result was detected in POC. The following anomalies were detected in POC: common trisomies (3),
monosomy X (2), common trisomy combined with 45, X (1), monosomy 21 (1), full rare trisomies (14),
mosaic rare trisomies (2) and copy number variations (4). Amongst the rare trisomies, trisomy 22
and trisomy 15 were the most frequent. Fetal fractions were from 3–12% (mean 5%). CfDNA results
were fully concordant with POC results in 40/57 samples. CfDNA results generated normal results
in 27/30 cases, and discrepant results in 3/30 cases of known normal cases. The two mosaic samples
(sample IDs 51 and 586) were not correctly identified with cfDNA testing; however, other imbalances
were detected in those samples. Sample ID 228 gave a monosomy 21 result on POC, but cfDNA testing
identified CNVs in several other chromosomes.
Four of the samples were from miscarriages where subchromosomal deletions and duplications
were identified by POC analysis (sample IDs 133, 202, 303 and 319). A 56 Mb duplication at 7q22.1q36.3
and a 21 Mb terminal duplication at 19q13.12q13.43 were detected by cfDNA analysis. A 70 Mb deletion
at 13q13.3q34, a 6 Mb terminal deletion at 7q36.2q36.3, a 9 Mb terminal duplication at 4q34.3q35.2 and
a 30 Mb terminal deletion at 5q33.1q35.3 were not detected by cfDNA analysis.
The results were grouped into three categories using different gestations, βhCG values and
fetal fraction cut offs, to see if this could improve the result calling between cfDNA and POC
cytogenetic analysis (Table 3). The gestation was split into four groups, <7 weeks, 7–8 weeks, ≥8 and
unknown gestation. As the gestation increased in these groups, the correctly identified chromosomal
abnormalities from cfDNA testing increased. The βhCG value was split into three groups of <8000,
8000–35,000 and >35,000 mIU/mL. As the βhCG value increased in these groups, the correctly identified
chromosomal abnormalities from cfDNA testing also increased. The fetal fraction groups were split
into three groups: <5, 5–8 and ≥9. Again, as fetal fraction groups increased so did the percentage of
correctly identified chromosomal abnormalities from cfDNA testing.
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Table 2. Analysis of cfDNA using a modified Illumina VeriSeq non-invasive prenatal testing (NIPT) solution v2 workflow compared to the genetic outcomes of













POC Results POC Sex CfDNA Results CfDNASex Fetal Fraction
4 7 + 2 2.8 19,247 40 2 Trisomy 22 Female NO ANOMALYDETECTED Female 4%
51 5 + 4 2 12,725 34 6 Mosaic trisomy 4 Male DETECTED: del (10)(p15.3q21.1) Male 4%
99 6 + 0 not recorded 5111 27 4 Trisomy 5 Male NO ANOMALYDETECTED Male 6%
133 not recorded not recorded 57,348 34 4
Terminal deletion at
7q36.2q36.3 (6 Mb) and
terminal duplication at
19q13.12q13.43 (21 Mb)
Female DETECTED: dup(19) (q13.12q13.43) Female 7%
163 8 + 4 20.1 13,466 24 3 Turners, 45 X Female DETECTED: XO Female 7%
164 6 + 0 9 6774 42 2 Trisomy 15 Female DETECTED: +15 Female 5%
175 8 + 0 No FP seen 5323 34 6 Turners, 45 X Female DETECTED: XO Female 5%
176 7 + 0 14 491 43 2 Trisomy 15 Female DETECTED: +15 Female 5%
202 6 + 0 5 13,819 29 4
Terminal duplication at
4q34.3q35.2 (9 Mb) and
terminal deletion at
5q33.1q35.3 (30 Mb)
Female NO ANOMALYDETECTED Female 4%





245 not recorded 6.5 14,762 33 3 Trisomy 22 Male NO ANOMALYDETECTED Male 4%
260 7 + 0 not recorded 5194 43 2 Trisomy 22 Male NO ANOMALYDETECTED Male 4%














POC Results POC Sex CfDNA Results CfDNASex Fetal Fraction
264 6 + 0 4 14,002 33 Notrecorded Trisomy 13. Female
DETECTED: +13;
+16 Female 4%
279 6 + 0 6 8429 40 4 Trisomy 7 Female DETECTED: +7 Female 12%
287 not recorded 4 notrecorded 42 0 Trisomy 12 Female DETECTED: +12 Female 4%
290 5 + 0 5.2 44,313 39 0 Trisomy 16 Female DETECTED: +16 Female 7%
303 6 + 0 1.9 34,087 35 3 Deletion at 13q13.3q34(70 Mb) Female
NO ANOMALY
DETECTED Female 5%
319 7 + 0 9.3 13,642 40 6 Duplication 7q22.1q36.3(56 Mb) Female
DETECTED: dup (7)
(q22.1q31.1) Female 7%
328 not recorded 4.4 2983 42 3 Trisomy 11 Female NO ANOMALYDETECTED Female 4%
400 5 + 6 4.6 29,052 42 5 Trisomy 22 Male DETECTED: +22 Male 3%
462 6 + 1 3 22,429 40 2 Trisomy 15 Male DETECTED: +15 Male 5%
519 9 + 3 26.31 100,638 28 6 Trisomy 21 Male DETECTED: +21 Male 10%
529 7 + 0 not recorded 21,171 39 5 Trisomy 21 andmonosomy X. Female DETECTED: +21 Female 5%
541 7 + 3 12.02 42,333 33 2 Trisomy 15 Female DETECTED: +15 Female 8%
586 6 + 0 5.28 22,435 41 2 Mosaic trisomy 17 Female DETECTED: del (6)(p25.1p22.3); +18 Female 4%
816 5 + 0 no FP seen 5852 40 3 Trisomy 18. Female NO ANOMALYDETECTED Female 4%
965 7 + 6 14.7 73,962 42 3 Trisomy 15 Male DETECTED: +15 Male INVALIDATED
CfDNA results labelled in green are concordant with POC results and results labelled in red are discordant with POC results.
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Table 3. CfDNA vs karyotype of POC.
CfDNA Results
Correctly Identified (%) Not Identified (%)
Total 43 (75.4) 14 (324.6)
Gestation (weeks)
<7 14 (66.7) 7 (33.3)
7–8 10 (76.9) 3 (23.1)
≥8 11 (100.0) 0 (0.0)
Unknown 8 (53.3) 7 (46.7)
βhCG
(mIU/mL)
<8000 9 (60.0) 6 (40.0)
8000–35,000 14 (66.7) 7 (33.3)
>35,000 19 (95.0) 1 (5.0)
Fetal Fraction (%)
<5 13 (59.1) 9 (40.9)
5–8 19 (79.2) 5 (20.8)
≥9 10 (100.0) 0 (0.0)
4. Discussions
Our cfDNA study cohort was recruited through Tommy’s National Centre for Miscarriage
Research, at Birmingham Women’s Hospital and University Hospital Coventry and Warwickshire.
In total, 102 samples were evaluated using modified VeriSeq NIPT V2 (Illumina), and 57 samples were
analysed with corresponding POC cytogenetic analysis.
The cfDNA analysis was separated into three categories for analysis (Table 3). Whilst some
chromosomal abnormalities were identified at lower fetal fraction, at <5% fetal fraction, only 60% of
samples were correctly identified, and of those, most were from euploid pregnancies. In contrast,
where the fetal fraction was ≥9%, 100% of cytogenetic results were correctly identified. In our study,
we note that the majority of abnormalities can be detected above 5% fetal fraction. However, it is
difficult to define an exact cut off due to the low sample numbers and biological variation.
The discrepancies we observed between the POC genetic results and the cfDNA testing
could be caused by confined placental mosaicism. CfDNA analysis tests DNA derived from the
placenta/cytotrophoblasts only, whereas the POC testing may consist of fetal tissue and whole placental
tissue. This could result in a discrepancy between the results. In two cases, mosaic genetic abnormalities
were identified in the POC analysis which cfDNA testing did not identify. These results could be due
to confined placental mosaicism for the trisomic cells or due to the current limitation of the method.
Mosaicism is difficult to diagnose with any methodology, and it is possible that cfDNA analysis could
become a helpful adjunct to current POC testing in detecting biologically relevant abnormal cell lines.
Tommy’s National Centre for Miscarriage Research is specialised in the care of families undergoing
recurrent miscarriage. These families are very aware of when they first become pregnant and benefit
from careful monitoring during their first trimester. Consequently, the miscarriages in our study cohort
were diagnosed earlier than in other studies. Clark-Ganheart et al. [6] recorded gestational ages of 16.9
(6.1–37.2) weeks, and Yaron et al. [7] recorded gestational ages 9.6 (5.1–13.6) weeks (Figure 2).
This study and others have demonstrated that in the majority of cases of pregnancy loss where
the pregnancy tissue is still in situ, it is possible to detect chromosomal abnormalities using cfDNA.
This study correctly identified 59% of chromosomal abnormalities with a 75% concordance to POC
results. In comparison, Clark-Ganheart et al. [6] had 87.5% concordant results where there was
an available cytogenetic result, and Yaron et al. [7] had 82% concordant results using pregnancy
loss-specific LLR thresholds. Using 50 cases as a training set, Yaron et al. [7] established a pregnancy
loss-specific LLR threshold. Overall detection was 82% on 86 non-mosaic cases. This was achieved after
identifying a pregnancy-loss-specific LLR based on a training set. This indicates that the LLR needed
for this cohort may need to be different from singleton pregnancies. In comparison, our study used the
standard NIPT LLR cut-offs to analyse cfDNA, and it is feasible that having a pregnancy-loss-specific
LLR would improve the detection rate. The next step in this study may be to conduct a trial using
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an algorithm similar to the one proposed by Yaron et al. [7], using a pipeline with modified LLRs to
optimise the detection rate of all autosomal trisomies for this cohort of patients.
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for more patients where there is no POC available. It is important to note that some chromosomal
abnormalities would still be missed if POC is not available. In cases where an unbalanced rearrangement
is identified that could be due to an inherited or de novo Robertsonian or reciprocal translocation,
parental karyotyping should be recommended to assess whether one (or both) of the parents is a carrier
of this translocation.
5. Conclusions
Knowing the genetic result of a pregnancy loss can be applied during counselling patients for the
prognosis of future pregnancies. It may also be helpful to provide psychological support and relief
from the guilt that can be associated with pregnancy loss.
Using cfDNA to identify whether a miscarriage was caused by chromosomal abnormalities would
have a huge clinical impact upon patients for whom conventional cytogenetic testing may not be
available, either due to the unavailability of pregnancy tissue for testing or patient preferences. However,
cfDNA testing is only feasible where the pregnancy remains in situ at the time of miscarriage diagnosis.
We have demonstrated that in some cases, cfDNA can be used to detect a genetic aberration in
miscarriages providing the maternal plasma sample is collected when the pregnancy tissue is still in
situ and in cases where there is enough fetal fraction. Further work is required to improve this testing
and to identify variables that can affect the overall results so that it may be applied clinically.
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